NCT03982160View on ClinicalTrials.gov

L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Chronic Kidney Disease
Interventions
DRUG

L-Arginine

Arginine Hydrochloride 60% concentration injection 15 g in 25 mL, contains arginine hydrochloride 600 mg/mL in water for injections to 25 mL.

OTHER

Placebo

Saline

Trial Locations (2)

19716

RECRUITING

University of Delaware, Newark

75390

RECRUITING

UT Southwestern, Dallas

All Listed Sponsors
lead

The University of Texas at Arlington

OTHER